Gilead Sciences (GILD) is a publicly traded Healthcare sector company. As of October 3, 2026, GILD trades at $144.50 with a market cap of $182.89B and a P/E ratio of -56.88. GILD moved -1.88% today. Year to date, GILD is +19.03%; over the trailing twelve months it is +30.92%. Its 52-week range spans $93.37 to $157.29. Analyst consensus is strong buy with an average price target of $159.11. Rallies surfaces GILD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for GILD, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $144.50 |
| Market Cap | $182.89B |
| P/E Ratio | -56.88 |
| EPS | $-2.60 |
| Dividend Yield | 0.82% |
| 52-Week High | $157.29 |
| 52-Week Low | $93.37 |
| Volume | 2.85M |
| Avg Volume | 0 |
| Revenue (TTM) | $30.46B |
| Net Income | $-3.24B |
| Gross Margin | 79.59% |
21 analysts cover GILD: 0 strong buy, 17 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $159.11.